Stockscreener 앱 받기
7.62
0.13%
0.010
시간 외 거래:
7.69
0.07
+0.92%
Biocryst Pharmaceuticals Inc 주식(BCRX)의 최신 뉴스
Trend Tracker for (BCRX) - Stock Traders Daily
JPMorgan Chase & Co. Decreases Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - MarketBeat
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Sees Significant Drop in Short Interest - MarketBeat
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Sees Significant Decline in Short Interest - Defense World
BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price Down 3.4%Time to Sell? - MarketBeat
BioCryst releases preliminary 2024 results, 2025 guidance - MSN
Be Bio secures $92m for haemophilia B and hypophosphatasia treatments - Pharmaceutical Technology
Evercore ISI Forecasts Strong Price Appreciation for BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock - Defense World
BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price Expected to Rise, Needham & Company LLC Analyst Says - Defense World
BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Down 3.4%Time to Sell? - MarketBeat
BioCryst price target raised to $12 from $10 at Evercore ISI - Yahoo Finance
BioCryst's SWOT analysis: stock outlook amid orladeyo's growth and pipeline shifts - Investing.com
BioCryst Pharmaceuticals (NASDAQ:BCRX) Price Target Raised to $12.00 - MarketBeat
BioCryst to Present at J.P. Morgan Conference - TipRanks
BioCryst Pharmaceuticals Releases Positive Financial Results and Guidance for 2025 - Defense World
BioCryst Pharmaceuticals Increases Wholesale Acquisition Cost for ORLADEYO®BioCryst Pharmaceuticals, Inc. has announced an increase in the wholesale acquisition cost (WAC) for ORLADEYO®, a medication used to treat various conditions in the United - Defense World
BioCryst stock target raised to $12 at Evercore ISI By Investing.com - Investing.com Canada
BioCryst projects $515-$535 million in ORLADEYO sales for 2025 By Investing.com - Investing.com Australia
Exploring High Growth Tech Stocks In January 2025 - Simply Wall St
BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap UpShould You Buy? - MarketBeat
BioCryst projects $515-$535 million in ORLADEYO sales for 2025 - Investing.com India
BioCryst Projects Strong Revenue Growth in 2024-2025 - TipRanks
BioCryst Announces Preliminary Full Year 2024 ORLADEYO® (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y) - The Manila Times
BioCryst Announces Preliminary Full Year 2024 ORLADEYO® - GlobeNewswire
BioCryst adjusts price of ORLADEYO in the U.S. By Investing.com - Investing.com Australia
Objective long/short (BCRX) Report - Stock Traders Daily
BioCryst adjusts price of ORLADEYO in the U.S. - Investing.com
BioCryst to Present at 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
BioCryst Pharmaceuticals to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
Cutaneous T-cell Lymphoma Market on Track for Major Expansion - openPR
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
BioCryst Awards Stock Options and RSUs to New Hires in Talent Acquisition Push - StockTitan
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Purchased by Principal Financial Group Inc. - MarketBeat
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Short Interest Down 10.7% in December - MarketBeat
BioCryst Announces Initiation of a Phase 1 Clinical Trial of BCX4161 for the Treatment of Hereditary - AOL
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
BioCryst Pharmaceuticals Insiders Added US$1.05m Of Stock To Their Holdings - Simply Wall St
The 4.5% return this week takes BioCryst Pharmaceuticals' (NASDAQ:BCRX) shareholders five-year gains to 127% - Yahoo Finance
Franklin Resources Inc. Acquires 168,790 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - MarketBeat
T-cell Lymphoma Market Key Players Analysis4SC AG, Acrotech - openPR
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Acquired by Geode Capital Management LLC - MarketBeat
Geode Capital Management LLC Buys 127,708 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Defense World
Wellington Management Group LLP Purchases Shares of 107,820 BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - MarketBeat
Trading (BCRX) With Integrated Risk Controls - Stock Traders Daily
XTX Topco Ltd Cuts Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - MarketBeat
KalVista stock wins new Buy at BofA (KALV:NASDAQ) - Seeking Alpha
State Street Corp Trims Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - MarketBeat
BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap DownHere's Why - MarketBeat
Biocryst Pharmaceuticals director Nancy Hutson sells $52,780 in stock - Investing.com India
1.44%
7.27%
자본화:
|
볼륨(24시간):